In his "If I were king" talk at the Moments of Change conference, the medical director at Retreat Premier Addiction Treatment Centers advocated a balanced and comprehensive approach to combating the opioid crisis.
The FDA is alerting providers and patients of the dangers of combining MAT drugs with benzodiazepines, a move that follows a recent change in labeling requirements for buprenorphine to indicate patients may require indefinite treatment.
A 2016 physician survey on the prescribing of buprenorphine does indicate that counselors and other specialty providers could help physicians overcome reluctance to prescribe the opioid dependence treatment.
New research has found that providing psychosocial counseling and avoiding prescribed opioids or benzodiazepines are among the variables that can reduce mortality rates in opioid use disorders. Medication treatment did not affect death rates.